Talazoparib beyond BRCA: A phase II trial of talazoparib monotherapy in BRCA1 and BRCA2 wild-type patients with advanced HER2-negative breast cancer or other solid tumors with a mutation in homologous recombination (HR) pathway genes.

被引：43
|
作者：
Gruber, Joshua James
Afghahi, Anosheh
Hatton, Alyssa
Scott, Danika
McMillan, Alex
Ford, James M.
Telli, Melinda L.
机构：
[1] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[2] Univ Colorado, Sch Med, Aurora, CO USA
[3] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.3006
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3006
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes
    Gruber, Joshua J.
    Afghahi, Anosheh
    Timms, Kirsten
    DeWees, Alyssa
    Gross, Wyatt
    Aushev, Vasily N.
    Wu, Hsin-Ta
    Balcioglu, Mustafa
    Sethi, Himanshu
    Scott, Danika
    Foran, Jessica
    McMillan, Alex
    Ford, James M.
    Telli, Melinda L.
    NATURE CANCER, 2022, 3 (10) : 1181 - +
  • [2] A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes
    Joshua J. Gruber
    Anosheh Afghahi
    Kirsten Timms
    Alyssa DeWees
    Wyatt Gross
    Vasily N. Aushev
    Hsin-Ta Wu
    Mustafa Balcioglu
    Himanshu Sethi
    Danika Scott
    Jessica Foran
    Alex McMillan
    James M. Ford
    Melinda L. Telli
    Nature Cancer, 2022, 3 : 1181 - 1191
  • [3] The Talazoparib Beyond BRCA (TBB) trial: A phase II clinical trial of talazoparib (BMN 673) in BRCA1 and BRCA2 wild-type patients with (i) advanced triple negative breast cancer (TNBC) and homologous recombination deficiency (HRD) as assessed by myriad genetics HRD assay, and (ii) advanced HER2-negative breast cancer (BC) with either a germline or somatic mutation in homologous recombination (HR) pathway genes
    Afghahi, A.
    Chang, P-J
    Ford, J. M.
    Telli, M. L.
    CANCER RESEARCH, 2016, 76
  • [4] Phase IV study evaluating effectiveness and safety of talazoparib in patients with locally advanced or metastatic HER2 negative breast cancer and a BRCA1 or BRCA2 mutation (ViTAL)
    Loirat, Delphine
    de labarre, Marie Duboys
    Essner, Christine
    Hrab, Ioana
    Thery, Jean-Christophe
    Jouannaud, Christelle
    Vuagnat, Perrine
    Soibinet-Oudot, Pauline
    Creisson, Anne
    Mailliez, Audrey
    Mouysset, Jean-Loup
    Salabert, Laura
    Dohollou, Nadine
    Fumet, Jean-David
    Rouge, Thibault De La Motte
    Vauthier, Jean-Michel
    Decrop, Maylis
    Pujol, Pascal
    CANCER RESEARCH, 2022, 82 (04)
  • [5] Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer
    Blum, Joanne L.
    Laird, A. Douglas
    Litton, Jennifer K.
    Rugo, Hope S.
    Ettl, Johannes
    Hurvitz, Sara A.
    Martin, Miguel
    Roche, Henri H.
    Lee, Kyung-Hun
    Goodwin, Annabel
    Chen, Ying
    Lanzalone, Silvana
    Chelliserry, Jijumon
    Czibere, Akos
    Hopkins, Julia F.
    Albacker, Lee A.
    Mina, Lida A.
    CLINICAL CANCER RESEARCH, 2022, 28 (07) : 1383 - 1390
  • [6] Cost-effectiveness of talazoparib for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US
    Pan, Junjie
    Ren, Ning
    Ren, Lanqi
    Yang, YiBei
    Xu, Qiaoping
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [7] Phase II study of the PARP inhibitor talazoparib (BMN-673) in advanced cancer patients with somatic alterations in BRCA1/2, mutations/deletions in PTEN or PTEN loss, a homologous recombination defect, mutations/deletions in other BRCA pathway genes and germline mutation S in BRCA1/2 (not breast or ovarian cancer).
    Piha-Paul, Sarina Anne
    Goldstein, Jennifer Brooke
    Hess, Kenneth R.
    Fu, Siqing
    Hong, David S.
    Janku, Filip
    Karp, Daniel D.
    Naing, Aung
    Subbiah, Vivek
    Tsimberidou, Apostolia Maria
    Wheler, Jennifer J.
    Zinner, Ralph
    Mills, Gordon B.
    Meric-Bernstam, Funda
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] Analysis of PTEN in two BRCA1 and BRCA2 wild-type familial breast cancer patients
    Akouchekian, Mansoureh
    Hemati, Simin
    Kachoei, Zohreh Ataei
    JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2015, 20 (06): : 629 - 630
  • [9] Phase II study of the PARP inhibitor talazoparib in advanced cancer patients with somatic alterations in BRCA1/2, mutations/deletions in PTEN or PTEN loss, aberrations in other BRCA pathway genes, and germline mutations in BRCA1/2 (not breast or ovarian cancer)
    Piha-Paul, Sarina A.
    Xiong, Wendy Wen
    Moss, Tyler
    Mostorino, Rosa M.
    Sedelmeier, Shelby
    Hess, Kenneth
    Fu, Siqing
    Hong, David
    Janku, Filip
    Karp, Daniel
    Naing, Aung
    Pant, Shubham
    Rodon, Jordi
    Subbiah, Vivek
    Tsimberidou, A. M.
    Yap, Timothy
    Javle, Milind
    Tapia, Coya
    Shaw, Kenna R.
    Eterovic, Karina
    Mills, Gordon B.
    Meric-Bernstam, Funda
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [10] Talazoparib versus Chemotherapy in Patients with HER2-Negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial
    Lee, Kyung-Hun
    Sohn, Joohyuk
    Goodwin, Annabel
    Usari, Tiziana
    Lanzalone, Silvana
    Im, Seock-Ah
    Kim, Sung-Bae
    CANCER RESEARCH AND TREATMENT, 2021, 53 (04): : 1084 - 1095
12345